Jaguar Health Files 8-K on Equity Sales
Ticker: JAGX · Form: 8-K · Filed: 2025-10-03T00:00:00.000Z
Sentiment: neutral
Topics: equity-sale, unregistered-securities
TL;DR
Jaguar Health sold more stock, could dilute existing holders.
AI Summary
On September 30, 2025, Jaguar Health, Inc. filed an 8-K report detailing unregistered sales of equity securities. The company, formerly known as Jaguar Animal Health, Inc., is incorporated in Delaware and headquartered in San Francisco, California.
Why It Matters
This filing indicates potential dilution for existing shareholders due to the issuance of new equity, which could impact the stock price.
Risk Assessment
Risk Level: medium — Unregistered sales of equity can signal financial distress or a need for capital, potentially leading to dilution and impacting stock value.
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- Jaguar Animal Health, Inc. (company) — Former company name
- September 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Francisco, California (location) — Principal executive offices
- 415-371-8300 (phone_number) — Registrant's telephone number
FAQ
What specific type of equity securities were sold?
The filing indicates 'Unregistered Sales of Equity Securities' but does not specify the exact type within this 8-K excerpt.
Were these sales part of a registered offering?
The filing explicitly states 'Unregistered Sales of Equity Securities,' indicating they were not registered with the SEC.
What is the date of the earliest event reported in this 8-K?
The earliest event reported is dated September 30, 2025.
What was Jaguar Health, Inc. formerly known as?
The company was formerly known as Jaguar Animal Health, Inc.
Where are Jaguar Health, Inc.'s principal executive offices located?
The principal executive offices are located at 200 Pine Street, Suite 400, San Francisco, California, 94104.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-10-03 16:30:13
Key Financial Figures
- $0.0001 — ich registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital M
- $600,000 — stock to such holder in exchange for a $600,000 reduction in the outstanding balance of
Filing Documents
- d43916d8k.htm (8-K) — 25KB
- 0001193125-25-230298.txt ( ) — 136KB
- jagx-20250930.xsd (EX-101.SCH) — 3KB
- jagx-20250930_lab.xml (EX-101.LAB) — 18KB
- jagx-20250930_pre.xml (EX-101.PRE) — 11KB
- d43916d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Form of Exchange Agreement (incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2019, filed on August 14, 2019). 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. By: /s/ Lisa A. Conte Name: Lisa A. Conte Title: President and Chief Executive Officer Date: October 3, 2025